CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 - Sometimes things come full circle. Fourteen years ago , CancerFree KIDS awarded its very first [...]
Bexion Pharmaceuticals, Inc. Announces Data at 2018 ASCO Annual Meeting from Ongoing Phase I BXQ-350 Clinical Trial
FOR IMMEDIATE RELEASE Covington, KY ~ June 12, 2018 - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of [...]
FOR IMMEDIATE RELEASE Covington, KY - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature one clinical poster presentation and three online publications at the [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857